Current State of Immune-Based Therapies for Glioblastoma | Zendy

Michael Lim | Zendy; Michael Weller | Zendy; E. Antonio Chiocca | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current State of Immune-Based Therapies for Glioblastoma

Author(s) -

Michael Lim,

Michael Weller,

E. Antonio Chiocca

Publication year - 2016

Publication title -

american society of clinical oncology educational book

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.463

H-Index - 35

eISSN - 1548-8756

pISSN - 1548-8748

DOI - 10.14694/edbk_159084

Subject(s) - glioblastoma , immunosuppression , medicine , immunotherapy , radiation therapy , kidney cancer , melanoma , lung cancer , immune system , chemotherapy , cancer , oncology , cancer research , immunology

Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research